---
title: "Endra Life Sciences | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281247612.md"
datetime: "2026-03-31T21:13:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281247612.md)
  - [en](https://longbridge.com/en/news/281247612.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281247612.md)
---

# Endra Life Sciences | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -8.93, missing the estimate of USD -6.59.

EBIT: As of FY2025, the actual value is USD -5.834 M.

#### Segment Information

ENDRA Life Sciences Inc. operates as a single reportable segment focusing on biotech and the development of its proprietary thermo-acoustic technology platform.

#### Revenue

ENDRA Life Sciences Inc. reported no revenue for the years ended December 31, 2025, and 2024, as its TAEUS technology has not yet been commercially sold.

#### Operational Metrics

-   **Net Loss:** The company reported a net loss of - $7,027,410 for the year ended December 31, 2025, which is an improvement compared to a net loss of - $11,507,947 for the year ended December 31, 2024.
-   **Operating Expenses:**
    -   **Research and Development (R&D):** R&D expenses decreased by 42% to $1,849,996 in 2025 from $3,190,293 in 2024, attributed to the completion of initial TAEUS product development and a shift to focusing on smaller trials.
    -   **Sales and Marketing:** Sales and marketing expenses decreased by 67% to $189,470 in 2025 from $571,040 in 2024, largely due to a reduction in personnel until clinical trials are complete.
    -   **General and Administrative (G&A):** G&A expenses decreased by 47% to $3,723,635 in 2025 from $7,055,814 in 2024, primarily due to an inventory reserve of $2,525,179 recorded in 2024 that was $0 in 2025.
-   **Other Expenses/Income:** Total other expenses were - $1,264,309 in 2025, mainly driven by changes in the fair value of digital assets and warrant expenses, compared to - $690,800 in 2024. Digital asset staking compensation was $5,121 in 2025, while changes in fair value of digital assets resulted in a loss of - $995,161 in 2025. Warrant expense was - $665,030 in 2025, significantly lower than - $7,323,685 in 2024.

#### Cash Flow

-   **Operating Activities:** Cash used in operating activities was - $5,182,558 in 2025, an improvement from - $7,400,547 in 2024.
-   **Investing Activities:** Cash used in investing activities was - $3,017,280 in 2025, which included $3,000,000 for the purchase of digital intangible assets, compared to - $12,796 in 2024.
-   **Financing Activities:** Cash provided by financing activities was $5,732,723 in 2025, including $4,514,482 from fundraising and $1,218,241 from common stock issuances, compared to $7,808,917 in 2024.

#### Unique Metrics

-   **Cash Balance:** As of December 31, 2025, ENDRA Life Sciences Inc. had $762,365 in cash.
-   **Accumulated Deficit:** The company’s accumulated deficit reached $110,465,509 as of December 31, 2025.
-   **Digital Assets:** As of December 31, 2025, the company held $2,009,960 in digital assets, primarily HYPE tokens, initially purchased for $3.0 million on October 23, 2025, which had an unrealized loss of - $995,161 recognized in earnings.

#### Outlook / Guidance

ENDRA Life Sciences Inc. implemented cost reduction measures in 2026, including headcount reduction and development prioritization, to extend its operating runway and focus on product improvements and regulatory strategy for its TAEUS liver application. These actions are expected to delay the timing of a future De Novo submission to the FDA for the TAEUS liver application. The company’s Board initiated a process in March 2026 to evaluate strategic alternatives and requires additional capital to fund clinical trials and commercialization plans beyond 2026.

### Related Stocks

- [NDRA.US](https://longbridge.com/en/quote/NDRA.US.md)

## Related News & Research

- [Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News](https://longbridge.com/en/news/286925108.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)
- [Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment | ACHV Stock News](https://longbridge.com/en/news/286952863.md)
- [Jacobs Growth Could Improve on Data Centers, Life Sciences Demand, RBC Says](https://longbridge.com/en/news/286945689.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)